The third IBA Cyclone® 70 shipped to CDNM, Moscow
After having passed its Factory acceptance tests, the third IBA Cyclone® 70 is leaving the IBA factory and starting its journey towards the final installation site in Moscow
Louvain-la-Neuve, Belgium, January 27th, 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy and radiopharmacy solutions, announces the shipment of its third Cyclone® 70 that will be delivered to the Centre for Development of Nuclear Medicine (CDNM) in Moscow, Russia
This 70 MeV Cyclotron will be dedicated to the production of new generation medical isotopes used mainly in the diagnosis of severe diseases.
This is in continuation of the achievement of IBA team of experts that have been commissioning the second machine in USA while working on the assembly & tests of the third cyclotron at the same time.
"I'm delighted by the spectacular year of IBA RadioPharma Solutions with the release and installation of the new PET machine, the Cyclone® KIUBE and delivering at the same time two Cyclone® 70 for the development of nuclear medicine and production of important cardiac PET generators." said Bruno Scutnaire, President of IBA RadioPharma Solutions.
"Thanks to IBA expertize, our Cyclone® 70 manufacturing and shipment is conducted in the best manner possible," said Alexander Khasin, CEO of the Centre for Development of Nuclear Medicine. "We are delighted by our collaboration with IBA and are confident that we will shortly reach our objective to supply the world with medical isotopes for the diagnosis and treatment of critical illnesses."
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com
The Centre for Development of Nuclear Medicine is a Moscow based company, whose main business areas are the supply of medical isotopes and radiopharmaceuticals for domestic and export markets, as well as medical services in Russia. Although the project is focused on routine production of radiopharmaceuticals, it also opens up several research isotopes not widely available in the world. www.cdnm.ru
For further information please contact:
Centre for Development of Nuclear Medicine
Public Relations Officer
IBA RadioPharma Solutions
Rebecca Lo bue